Innova Captab reported strong Q3 FY26 results, with revenue from operations at ₹450.3 crores and EBIDTA at ₹71.1 crores. The company registered YoY revenue growth of 42.3% and EBIDTA growth of 39.6%. Management highlighted disciplined execution and strategic expansion as key drivers. A recent quality compliance certificate will further expand the company’s international reach.
Financial Performance Highlights
Innova Captab announced its financial results for Q3 FY26, showcasing significant growth in revenue and profitability. Key highlights from the announcement include:
- Revenue from operations grew by 42.3% YoY, reaching ₹450.3 crores in Q3 FY26 compared to ₹316.5 crores in Q3 FY25.
- EBIDTA increased by 39.6% YoY, amounting to ₹71.1 crores in Q3 FY26 versus ₹50.9 crores in Q3 FY25. The EBIDTA margin for the quarter was 15.8%.
- Profit after tax (PAT) for Q3 FY26 stood at ₹42.1 crores, reflecting a growth of 23%. The PAT margin was 9.4%.
Nine-Month Performance (9M FY26)
The company also reported its performance for the nine months ended December 31, 2025:
- Revenue from operations for 9M FY26 totaled ₹1182.2 crores compared to ₹928.9 crores in 9M FY25, representing a growth of 27%.
- EBIDTA for 9M FY26 reached ₹183.7 crores, up from ₹147.1 crores in 9M FY25, a growth of 25%. EBIDTA margin was 15.5%.
- Profit after tax for 9M FY26 was ₹102.8 crores, with a PAT margin of 8.7%.
Management Commentary
According to Mr. Vinay Lohariwala, Managing Director, Innova Captab’s strong performance in Q3 FY26 and 9M FY26 underscores disciplined execution. Improved client engagement in the CDMO business and strategic geographic expansion in the Branded Generics vertical contributed to the company’s success. Receiving GMP Compliance from UK-MHRA for the Cephalosporin, Baddi unit and from PIC/s for Jammu facility further demonstrates adherence to global quality standards.
Source: BSE
